Safety profiles of novel agent therapies in CLL

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):354-357. doi: 10.1182/asheducation-2017.1.354.

Abstract

A 70-year-old man with relapsed/refractory chronic lymphocytic leukemia has multiple comorbidities including atrial fibrillation (on warfarin for anticoagulation), irritable bowel syndrome, and chronic renal insufficiency. Two years ago, he received bendamustine and rituximab as first-line therapy for chronic lymphocytic leukemia and achieved partial response, but now has relapsed. Fluorescence in situ hybridization cytogenetics reveals deletion 17p. Which novel agent would you recommend for this patient?

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / genetics
  • Atrial Fibrillation / metabolism
  • Atrial Fibrillation / pathology
  • Chromosome Deletion
  • Chromosomes, Human, Pair 17
  • Comorbidity
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Irritable Bowel Syndrome / genetics
  • Irritable Bowel Syndrome / metabolism
  • Irritable Bowel Syndrome / pathology
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Male
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / genetics
  • Renal Insufficiency, Chronic / metabolism
  • Renal Insufficiency, Chronic / pathology
  • Safety*
  • Smith-Magenis Syndrome
  • Warfarin / therapeutic use*

Substances

  • Antineoplastic Agents
  • Warfarin

Supplementary concepts

  • Chromosome 17 deletion